ClinicalTrials.gg
Active, not recruitingNCT03675308KEEPsAKE 1Updated Aug 5, 2025Results posted

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

A Phase 3 interventional study of Placebo and Risankizumab in Psoriatic Arthritis, sponsored by AbbVie. Active, not recruiting at 256 sites in 39 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
964
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Enrollment
2nd of 11
964 · median 246
Started
2019
with 1 other
Phase 3
5 of 34
1 open now
Registered
24th of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 24th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).

Read the detailed description

The study consists of a Screening Period (approximately 35 days), Period 1, Period 2, and a 20-week Follow-up Period. Period 1 is a 24-week randomized, double-blind, placebo-controlled, parallel-group treatment period. Period 2 is the long-term treatment period and starts at Week 24. To maintain the blind to the original treatment allocation, treatment at the Week 24 Visit is blinded: participants randomized to placebo receive blinded risankizumab 150 mg, and participants randomized to risankizumab receive blinded placebo. At Week 28 and for the remaining dosing visits (to Week 316), all participants are to receive open-label risankizumab 150 mg every 12 weeks. Participants will remain blinded to the original randomization allocation for the duration of the study. The total study duration is 336 weeks including a telephone call 140 days (20 weeks) after last dose of study drug.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at the Screening Visit.
  • Participant has active disease at Baseline defined as ≥ 5 tender joints (based on 68 joint counts) and ≥ 5 swollen joints (based on 66 joint counts)
  • Diagnosis of active plaque psoriasis with at least one psoriatic plaque of ≥ 2 cm diameter or nail changes consistent with psoriasis at Screening Visit.
  • Participant has demonstrated an inadequate response or intolerance to or for conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) therapy(ies).
  • Presence of either at Screening:

    • ≥ 1 erosion on radiograph as determined by central imaging review or;
    • High sensitivity C-reactive protein (hsCRP) ≥ 3.0 mg/L.

Exclusion criteria

Exclusion Criteria:

  • Participant is considered by investigator, for any reason, to be an unsuitable candidate for the study.
  • Participant has a known to risankizumab.
  • Participant has previous treatment with biologic agent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
964 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

    Biological: Placebo · Biological: Risankizumab

  • Experimental
    Risankizumab

    Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

    Biological: Placebo · Biological: Risankizumab

Interventions

  • BiologicalPlacebo

    Placebo for risankizumab administered by subcutaneous injection

  • BiologicalRisankizumab

    Risankizumab administered by subcutaneous injection

    Also known as: ABBV-066, BI 655066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline In Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24

    The Health Assessment Questionnaire Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24

    PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from Baseline in PASI score.

    Time frame: Baseline and Week 24

  3. Percentage of Participants With an ACR20 Response at Week 16

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 16

  4. Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

    A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 15 (VAS from 0 to 100) * Patient's Global Assessment of disease activity ≤ 20 (VAS from 0 to 100) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, for an overall score range from 0 to 6)

    Time frame: Week 24

  5. Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 24

    The investigator assessed each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (\>30% of the nail), pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (\> 50 pits present), and nail plate crumbling on a scale of 0 (no crumbling) to 3 (\>50% of nail has crumbling) and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula. The mNAPSI score is calculated as the sum of all the components for all of the participant's fingernails giving a range of possible scores from 0 (absence of nail psoriasis) to 130 (the most severe nail psoriasis). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 24

  6. Change From Baseline in Fingernail-Physician Global Assessment (PGA-F)

    The PGA-F is a clinician-rated outcomes assessment used to measure the severity of signs and symptoms associated with fingernail psoriasis. Participant's fingernails were assessed separately for nail bed signs and nail matrix signs of disease on a scale from 0 (clear) to 4 (severe). A participant's overall global score is the worse of the nail bed score and nail matrix score. For example, if a participant had a nail bed score '2' and a nail matrix score of '4,' this participant's overall score was '4.' A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 24

  7. Percentage of Participants With Resolution of Enthesitis at Week 24

    Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst). To increase the sample size due to the smaller number of participants with enthesitis at Baseline, the pre-specified analysis of the resolution of enthesitis included pooled data from KEEPsAKE 1 (this study) and the companion study KEEPsAKE 2 (M15-998; NCT03671148).

    Time frame: Week 24

  8. Percentage of Participants With Resolution of Dactylitis at Week 24

    Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. LDI basic is a score based on finger circumference and tenderness, assessed across all digits. The LDI basic measures the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot, using a minimum difference of 10% to define a dactylitic digit. The ratio of circumference is multiplied by a tenderness score (1 for tender, 0 for non-tender). If both sides of a digit are considered involved, or the circumference of the contralateral digit cannot be obtained, a standard reference table is used. Scores from each digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis. To increase sample size due to the smaller number of participants with dactylitis at Baseline, the pre-specified analysis of the resolution of dactylitis included pooled data from KEEPsAKE 1 (this study) and the companion study KEEPsAKE 2 (M15-998; NCT03671148).

    Time frame: Week 24

  9. Change From Baseline in PsA Modified Total Sharp Score (mTSS) at Week 24

    The Sharp-van der Heijde modified scoring method for PsA measures the level of joint damage from radiographs of the hands and feet, and was assessed by 2 independent, blinded readers. Joint erosion severity was assessed in 20 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 320 (worst). Joint space narrowing (JSN) was assessed in 20 joints of each hand and wrist, and 6 joints of each foot, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 208 (worst). Joints with gross osteolysis or pencil in cup were assigned the maximum score for both erosions and JSN. The total mTSS score is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 528 (worst).

    Time frame: Baseline and Week 24

  10. Change From Baseline In 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from Baseline score indicates improvement.

    Time frame: Baseline and Week 24

  11. Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 24

  12. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 24

  13. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 24

07

Results

Posted Feb 24, 2022

Participant flow

Participants were enrolled at 186 sites in 38 countries globally. The study includes a 24-week double-blind placebo-controlled treatment period (Period 1) and an ongoing 184-week open-label treatment period (Period 2). Results are reported for Period 1 which was from 25 March 2019 to 8 October 2020.

Participant flow — Overall Study
MilestonePlaceboRisankizumab
Started481483
Completed467473
Not completed1410
Withdrew: Adverse event32
Withdrew: Withdrawal by subject64
Withdrew: Lost to follow-up30
Withdrew: Lack of efficacy11
Withdrew: Coronavirus disease-2019 (covid-19) logistical restrictions12
Withdrew: Other01

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2433.5 (29.3 to 37.8)57.3 (52.9 to 61.8)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Response rate difference: 24.0 · 95% CI 18.0 to 30.0Response Rate Difference = Risankizumab - Placebo
SecondaryChange From Baseline In Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24

The Health Assessment Questionnaire Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline In Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline In Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24-0.11 (-0.16 to -0.06)-0.31 (-0.36 to -0.27)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Least squares (ls) mean difference: -0.20 · 95% CI -0.26 to -0.14Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from Baseline in PASI score.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 249.9 (6.4 to 13.5)52.3 (46.4 to 58.3)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Response rate difference: 42.5 · 95% CI 35.6 to 49.3Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With an ACR20 Response at Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR20 Response at Week 16
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an ACR20 Response at Week 1633.4 (28.9 to 37.9)56.3 (51.7 to 60.8)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Response rate difference: 23.1 · 95% CI 16.8 to 29.4Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 15 (VAS from 0 to 100) * Patient's Global Assessment of disease activity ≤ 20 (VAS from 0 to 100) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, for an overall score range from 0 to 6)

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 2410.2 (7.5 to 12.9)25.0 (21.2 to 28.9)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Response rate difference: 14.8 · 95% CI 10.2 to 19.4Response Rate Difference = Risankizumab - Placebo
SecondaryChange From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 24

The investigator assessed each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (\>30% of the nail), pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (\> 50 pits present), and nail plate crumbling on a scale of 0 (no crumbling) to 3 (\>50% of nail has crumbling) and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula. The mNAPSI score is calculated as the sum of all the components for all of the participant's fingernails giving a range of possible scores from 0 (absence of nail psoriasis) to 130 (the most severe nail psoriasis). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 24-5.57 (-6.70 to -4.44)-9.76 (-10.95 to -8.58)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Ls mean difference: -4.19 · 95% CI -5.70 to -2.68Difference = Risankizumab - Placebo
SecondaryChange From Baseline in Fingernail-Physician Global Assessment (PGA-F)

The PGA-F is a clinician-rated outcomes assessment used to measure the severity of signs and symptoms associated with fingernail psoriasis. Participant's fingernails were assessed separately for nail bed signs and nail matrix signs of disease on a scale from 0 (clear) to 4 (severe). A participant's overall global score is the worse of the nail bed score and nail matrix score. For example, if a participant had a nail bed score '2' and a nail matrix score of '4,' this participant's overall score was '4.' A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Fingernail-Physician Global Assessment (PGA-F)
score on a scalePlaceboRisankizumab
Change From Baseline in Fingernail-Physician Global Assessment (PGA-F)-0.4 (-0.5 to -0.3)-0.8 (-1.0 to -0.7)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Ls mean difference: -0.4 · 95% CI -0.6 to -0.3Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With Resolution of Enthesitis at Week 24

Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst). To increase the sample size due to the smaller number of participants with enthesitis at Baseline, the pre-specified analysis of the resolution of enthesitis included pooled data from KEEPsAKE 1 (this study) and the companion study KEEPsAKE 2 (M15-998; NCT03671148).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With Resolution of Enthesitis at Week 2434.8 (30.4 to 39.2)48.4 (43.8 to 53.1)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Response rate difference: 13.9 · 95% CI 7.6 to 20.2Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With Resolution of Dactylitis at Week 24

Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. LDI basic is a score based on finger circumference and tenderness, assessed across all digits. The LDI basic measures the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot, using a minimum difference of 10% to define a dactylitic digit. The ratio of circumference is multiplied by a tenderness score (1 for tender, 0 for non-tender). If both sides of a digit are considered involved, or the circumference of the contralateral digit cannot be obtained, a standard reference table is used. Scores from each digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis. To increase sample size due to the smaller number of participants with dactylitis at Baseline, the pre-specified analysis of the resolution of dactylitis included pooled data from KEEPsAKE 1 (this study) and the companion study KEEPsAKE 2 (M15-998; NCT03671148).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With Resolution of Dactylitis at Week 2451.0 (44.1 to 57.8)68.1 (61.4 to 74.7)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Response rate difference: 16.9 · 95% CI 7.5 to 26.4Response Rate Difference = Risankizumab - Placebo
SecondaryChange From Baseline in PsA Modified Total Sharp Score (mTSS) at Week 24

The Sharp-van der Heijde modified scoring method for PsA measures the level of joint damage from radiographs of the hands and feet, and was assessed by 2 independent, blinded readers. Joint erosion severity was assessed in 20 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 320 (worst). Joint space narrowing (JSN) was assessed in 20 joints of each hand and wrist, and 6 joints of each foot, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 208 (worst). Joints with gross osteolysis or pencil in cup were assigned the maximum score for both erosions and JSN. The total mTSS score is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 528 (worst).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in PsA Modified Total Sharp Score (mTSS) at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline in PsA Modified Total Sharp Score (mTSS) at Week 240.32 (0.11 to 0.53)0.23 (0.02 to 0.44)
Statistical analysis
  • Placebo vs Risankizumab · ANCOVA · p = 0.496 (All primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment via a fixed sequence testing procedure to control the family-wise type I error rate at α=0.05 (two- sided).) · Ls mean difference: -0.09 · 95% CI -0.36 to 0.17Difference = Risankizumab - Placebo
SecondaryChange From Baseline In 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from Baseline score indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline In 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline In 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 243.20 (2.50 to 3.89)6.52 (5.83 to 7.20)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = <0.001 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at the change from Baseline in PsA-mTSS comparison.) · Ls mean difference: 3.32 · 95% CI 2.42 to 4.22Difference = Risankizumab - Placebo
SecondaryChange From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
score on a scalePlaceboRisankizumab
Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 243.9 (3.1 to 4.7)6.5 (5.6 to 7.3)
Statistical analysis
  • Placebo vs Risankizumab · Mixed Effect Model Repeated Measurement · p = <0.001 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at the change from Baseline in PsA-mTSS comparison.) · Ls mean difference: 2.6 · 95% CI 1.5 to 3.7Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 2411.3 (8.4 to 14.1)33.4 (29.2 to 37.7)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 22.2 · 95% CI 17.3 to 27.2Response Rate Difference = Risankizumab - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24
percentage of participantsPlaceboRisankizumab
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 244.7 (2.8 to 6.7)15.3 (12.0 to 18.5)
Statistical analysis
  • Placebo vs Risankizumab · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 10.5 · 95% CI 6.9 to 14.2Response Rate Difference = Risankizumab - Placebo

Adverse events

Collected over From first dose of study drug to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/481 (0%)18/481 (3.7%)0/481 (0%)
Risankizumab1/483 (0.2%)12/483 (2.5%)0/483 (0%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPlaceboRisankizumab
PNEUMONIAInfections and infestations2/4811/483
ANAEMIABlood and lymphatic system disorders1/4810/483
IRON DEFICIENCY ANAEMIABlood and lymphatic system disorders1/4810/483
ANGINA UNSTABLECardiac disorders1/4810/483
VERTIGOEar and labyrinth disorders1/4810/483
DUODENAL ULCERGastrointestinal disorders1/4810/483
INTESTINAL OBSTRUCTIONGastrointestinal disorders1/4810/483
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/4810/483
APPENDICITIS PERFORATEDInfections and infestations1/4810/483
CELLULITISInfections and infestations1/4811/483

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboRisankizumabTotal
Mean51.2 ± 12.1051.3 ± 12.2151.3 ± 12.15
Age, Customized
Age, Customized(Participants)PlaceboRisankizumabTotal
< 65 years408414822
≥ 65 years7369142
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRisankizumabTotal
Female247231478
Male234252486
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRisankizumabTotal
Hispanic or Latino9293185
Not Hispanic or Latino389390779
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRisankizumabTotal
White451454905
Black or African American246
Asian221335
Native Hawaiian or Other Pacific Islander134
American Indian or Alaska Native011
Multiple5813
Current Use of csDMARD
Current Use of csDMARD(Participants)PlaceboRisankizumabTotal
Yes364366730
No117117234
Extent of Psoriasis
Extent of Psoriasis(Participants)PlaceboRisankizumabTotal
< 3% BSA209210419
≥ 3% BSA272273545
Presence of Dactylitis
Presence of Dactylitis(Participants)PlaceboRisankizumabTotal
Yes147148295
No334335669

13 further baseline measures are reported on the registry.

08

Study locations

256 sites
  • Pinnacle Research Group /ID# 167955
    Anniston, Alabama 36207, United States
  • Sun Valley Arthritis Center Ltd. /ID# 200270
    Peoria, Arizona 85381, United States
  • AZ Arthritis and Rheumotology Research, PLLC /ID# 209873
    Phoenix, Arizona 85032-9306, United States
  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 209875
    Tucson, Arizona 85704, United States
  • Southern Arizona VA Health Care System /ID# 209247
    Tucson, Arizona 85723, United States
  • Arthritis and Rheumatism Associates /ID# 209882
    Jonesboro, Arkansas 72401-6251, United States
  • Valerius Medical Group & Research Center /ID# 207428
    Los Alamitos, California 90720-5402, United States
  • Rheumatology Center of San Diego /ID# 201642
    San Diego, California 92128-2549, United States
  • Inland Rheum Clin Trials Inc. /ID# 201641
    Upland, California 91786, United States
  • Medvin Clinical Research /ID# 211127
    Whittier, California 90606, United States
  • New England Research Associates, LLC /ID# 207237
    Bridgeport, Connecticut 06606-1827, United States
  • Danbury Clinical Research, LLC /ID# 209517
    Danbury, Connecticut 06810, United States
  • Arthritis & Osteoporosis Center /ID# 207236
    Hamden, Connecticut 06518, United States
  • Arthritis & Rheumatic Disease Specialties /ID# 210802
    Aventura, Florida 33180, United States
  • Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 211099
    Boca Raton, Florida 33486, United States
  • SIMED Health, LLC /ID# 207461
    Gainesville, Florida 32607-2817, United States
  • Sweet Hope Research Specialty Inc /ID# 209393
    Hialeah, Florida 33016-1897, United States
  • Jacksonville Center for Clinical Research /ID# 209876
    Jacksonville, Florida 32216, United States
  • Rheum Assoc of Central FL /ID# 201622
    Orlando, Florida 32806, United States
  • HMD Research LLC /ID# 208427
    Orlando, Florida 32819, United States
  • IRIS Research and Development, LLC /ID# 208955
    Plantation, Florida 33324, United States
  • ForCare Clinical Research /ID# 168034
    Tampa, Florida 33613-1244, United States
  • Arthritis and Rheumatology /ID# 168046
    Atlanta, Georgia 30342, United States
  • Affinity Clinical Research /ID# 210816
    Oak Brook, Illinois 60523-1245, United States
  • OrthoIllinois /ID# 205300
    Rockford, Illinois 61114-4937, United States
  • Springfield Clinic /ID# 200244
    Springfield, Illinois 62702-3749, United States
  • Klein and Associates MD /ID# 169483
    Hagerstown, Maryland 21740, United States
  • The Center for Rheumatology and Bone Research /ID# 168017
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Gr /ID# 168019
    Worcester, Massachusetts 01605, United States
  • Advanced Rheumatology, PC /ID# 168042
    Lansing, Michigan 48910, United States
  • June DO, PC /ID# 208915
    Lansing, Michigan 48910, United States
  • St. Paul Rheumatology /ID# 208471
    Eagan, Minnesota 55121, United States
  • Logan Health Research /ID# 213707
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC /ID# 208670
    Lincoln, Nebraska 68516, United States
  • Center for Rheumatology LLP /ID# 207313
    Albany, New York 12203-3710, United States
  • NYU Langone Ambulatory Care Brooklyn Heights /ID# 207310
    Brooklyn, New York 11201, United States
  • Joint & Muscle Research Instit /ID# 208620
    Charlotte, North Carolina 28204, United States
  • Medication Management, LLC /ID# 211734
    Greensboro, North Carolina 27408, United States
  • Coastal Carolina Health Care /ID# 208619
    New Bern, North Carolina 28562, United States
  • Velocity Clinical Research /ID# 200452
    Blue Ash, Ohio 45242-3763, United States
  • Marietta Memorial Hospital /ID# 210179
    Marietta, Ohio 45750-1635, United States
  • Paramount Medical Research Con /ID# 201583
    Middleburg Heights, Ohio 44130, United States
  • STAT Research, Inc. /ID# 213805
    Springboro, Ohio 45066, United States
  • Health Research of Oklahoma /ID# 168027
    Oklahoma City, Oklahoma 73103-2400, United States
  • Altoona Ctr Clinical Res /ID# 168037
    Duncansville, Pennsylvania 16635, United States
  • Allegheny Health Network Research Institute /ID# 210349
    Pittsburgh, Pennsylvania 15212-4756, United States
  • Clinical Research Ctr Reading /ID# 168070
    Wyomissing, Pennsylvania 19610, United States
  • Nashville Arthritis and Rheumatology /ID# 168069
    Nashville, Tennessee 37203, United States
  • Amarillo Ctr for Clin Research /ID# 208347
    Amarillo, Texas 79124, United States
  • Precision Comprehensive Clinical Research Solutions /ID# 208386
    Colleyville, Texas 76034, United States
  • Dallas VA Medical Center /ID# 208389
    Dallas, Texas 75216, United States
  • Precision Comprehensive Clinical Research Solutions /ID# 210597
    Fort Worth, Texas 76107, United States
  • Advanced Rheumatology of Houston /ID# 208354
    The Woodlands, Texas 77382, United States
  • DM Clinical Research /ID# 208351
    Tomball, Texas 77375, United States
  • Kadlec Clinic Rheumatology /ID# 207969
    Kennewick, Washington 99336, United States
  • Rheumatology and Pulmonary Clinic /ID# 200446
    Beckley, West Virginia 25801, United States
  • Aurora Rheumatology and Immunotherapy Center /ID# 168066
    Franklin, Wisconsin 53132, United States
  • Holy Family Memorial, Inc. /ID# 209387
    Manitowoc, Wisconsin 54220, United States
  • Gundersen Clinic, Ltd /ID# 209459
    Onalaska, Wisconsin 54650, United States
  • Framingham Centro Medico /ID# 210409
    La Plata, Buenos Aires 1902, Argentina
  • Hospital General de Agudos J. M. Ramos Mejia /ID# 169164
    Buenos Aires, Ciuadad Autonoma de Buenos Aires 1221, Argentina
  • Hospital Italiano de Buenos Aires /ID# 208474
    Ciudad Autonoma Buenos Aires, Ciuadad Autonoma de Buenos Aires 1199, Argentina
  • DOM Centro de Reumatologia /ID# 208479
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1111, Argentina
  • Fundacion CIDEA /ID# 210494
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1121, Argentina
  • Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich /ID# 211622
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1426, Argentina
  • Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 169163
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto CAICI /ID# 169168
    Rosario, Santa Fe Province 2000, Argentina
  • Centro Medico Privado de Reumatologia /ID# 208343
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Duplicate_Inst de Rehab Psicofisica /ID# 214681
    Buenos Aires, 2201, Argentina
  • Duplicate_Hospital Privado Univesitario /ID# 211623
    Córdoba, 5016, Argentina
  • Cimer /Id# 169167
    San Miguel de Tucumán, 4000, Argentina
  • The Canberra Hospital /ID# 207592
    Garran, Australian Capital Territory 2605, Australia
  • Royal Brisbane and Women's Hospital /ID# 212785
    Herston, Queensland 4029, Australia
  • Rheumatology Research Unit Sunshine Coast /ID# 207200
    Maroochydore, Queensland 4558, Australia
  • Griffith University /ID# 207505
    Southport, Queensland 4222, Australia
  • Flinders Medical Centre /ID# 210562
    Bedford Park, South Australia 5042, Australia
  • Emeritus Research /ID# 207202
    Camberwell, Victoria 3124, Australia
  • Monash Medical Centre /ID# 208034
    Clayton, Victoria 3168, Australia
  • Duplicate_UZ Ghent /ID# 210036
    Ghent, Oost-Vlaanderen 9000, Belgium
  • ReumaClinic /ID# 208213
    Genk, 3600, Belgium
  • ZNA - Jan Palfijn /ID# 208212
    Merksem, 2170, Belgium
  • University Clinical Centre of the Republic of Srpska /ID# 208268
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • University Clinical Centre of the Republic of Srpska /ID# 208269
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • University Clinical Centre of the Republic of Srpska /ID# 210047
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • Clinical Center University of Sarajevo /ID# 208272
    Sarajevo, 71000, Bosnia and Herzegovina
  • SER - Serviços Especializados em Reumatologia /ID# 207489
    Salvador, Estado de Bahia 40150-150, Brazil
  • CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 207496
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • EDUMED Educacao em Saude S/S L /ID# 207488
    Curitiba, Paraná 80440-080, Brazil
  • LMK Sevicos Medicos S/S /ID# 207491
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas /ID# 207493
    São Paulo, 01228-200, Brazil
  • Medical center Medconsult /ID# 211399
    Pleven, 5800, Bulgaria
  • Medical center Excelsior /ID# 167741
    Sofia, 1407, Bulgaria
  • Diagnostic consultative center 17 Sofia /ID# 210506
    Sofia, 1505, Bulgaria
  • Military Medical Academy Multiprofile Hospital /ID# 210829
    Sofia, 1606, Bulgaria
  • Percuro Clinical Research, Ltd /ID# 169601
    Victoria, British Columbia V8V 3M9, Canada
  • Manitoba Clinic /ID# 206819
    Winnipeg, Manitoba R3A 1M3, Canada
  • CIADS Research Co Ltd /ID# 169600
    Winnipeg, Manitoba R3N 0K6, Canada
  • SKIN Centre for Dermatology /ID# 169604
    Peterborough, Ontario K9J 5K2, Canada
  • K. Papp Clinical Research /ID# 169603
    Waterloo, Ontario N2J 1C4, Canada
  • Groupe de Recherche en Maladies Osseuses Inc /ID# 169598
    Sainte-Foy, Quebec G1V 3M7, Canada

Showing the first 100 of 256 sites across 39 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022 Feb;81(2):225-231. doi: 10.1136/annrheumdis-2021-221019. Epub 2021 Dec 15. PubMed 34911706 ↗
  • Gossec L, Balanescu A, D'Agostino MA, Ogdie A, Sewerin P, Deng Y, Shi L, Sugimoto Y, Zhong S, Xing Y, Lippe R, Kishimoto M. Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naive patients in two phase 3 clinical trials. Arthritis Res Ther. 2025 Nov 29;28(1):2. doi: 10.1186/s13075-025-03670-0. PubMed 41318485 ↗
  • Ostor A, Van den Bosch F, Papp K, Keiserman M, Blanco R, Crowley A, White D, Biljan A, Madihlaba T, Carter K, Liu F, Soliman AM, Ashley D, Chen M, Glotfelty L, Kivitz A. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials. Rheumatol Ther. 2025 Dec;12(6):1103-1123. doi: 10.1007/s40744-025-00793-3. Epub 2025 Sep 30. PubMed 41028616 ↗
  • Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Oct;11(5):1403-1412. doi: 10.1007/s40744-024-00706-w. Epub 2024 Aug 9. PubMed 39120849 ↗
  • Kwatra SG, Khattri S, Amin AZ, Ranza R, Kaplan B, Shi L, Padilla B, Soliman AM, McGonagle D. Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials. Dermatol Ther (Heidelb). 2024 Jun;14(6):1517-1530. doi: 10.1007/s13555-024-01174-4. Epub 2024 May 13. PubMed 38739215 ↗
  • Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Carter K, Lippe R, Photowala H, Drogaris L, Soliman AM, Chen M, Padilla B, Behrens F. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatol Ther. 2024 Jun;11(3):617-632. doi: 10.1007/s40744-024-00654-5. Epub 2024 Mar 18. PubMed 38498141 ↗
  • Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2023 Jun 1;62(6):2113-2121. doi: 10.1093/rheumatology/keac607. PubMed 36282530 ↗
  • Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30. PubMed 36178584 ↗
  • Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, Eldred A, Behrens F. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology (Oxford). 2023 Feb 1;62(2):629-637. doi: 10.1093/rheumatology/keac342. PubMed 35801915 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2020, 18 months.

Results were first posted in Feb 2022, 1 year 4 months after primary completion. A results delay was requested in Sep 2021.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 18 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2018
First posted
Sep 18, 2018
StartActual
Mar 25, 2019
Primary completionActual
Oct 8, 2020
CompletionEst.
Sep 28, 2026
Results delay requested
Sep 21, 2021
Results first posted
Feb 24, 2022
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03675308
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 18, 2018
Start date
Mar 25, 2019
Primary completion
Oct 8, 2020
Completion
Sep 28, 2026 (estimated)
Results posted
Feb 24, 2022
Last update
Aug 5, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion